The effect of sub-inhibitory concentrations of rifaximin on urease production and on other virulence factors expressed by Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa and Staphylococcus aureus

References

• Gillis GC, Brogden RN. Rifaximin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria. Drugs. 1995;49:467–84.10.2165/00003495-199549030-00009
   PubMed Web of Science ®Google Scholar
• Jiang ZD, Dupont HL. Rifaximin: in vitro and in vivo antibacterial activity – a review. Chemotherapy. 2005;51(Suppl 1):67–72.10.1159/000081991
   PubMed Web of Science ®Google Scholar
• Alvisi V, D’Ambrosi A, Lo Ponte A, Pazzi P, Greco A, Zangirolami A, et al. Rifaximin, a rifampicin derivative for use in the treatment of intestinal bacterial infectious in seriously disabled patients. J Int Med Res. 1987;15:49–56.
   PubMed Web of Science ®Google Scholar
• Hoover WW, Gerlach EH, Hoban DJ, Eliopolus GM, Pfaller MA, Jones RN. Antimicrobial activity and spectrum of rifaximin, a new topical rifamycin derivative. Diagn Microbiol Infect Dis. 1993;16:111–8.10.1016/0732-8893(93)90004-Q
   PubMed Web of Science ®Google Scholar
• Jiang ZD, Ke S, Palazzini E, Riopel L, Dupont HL. In vitro activity and fecal concentration of rifaximin after oral administration. Antimicrob Agents Chemother. 2000;44:2205–6.10.1128/AAC.44.8.2205-2206.2000
   PubMed Web of Science ®Google Scholar
• Sierra JM, Ruiz J, Navia MM, Vargas M, Vila J. In vitro activity of rifaximin against enteropathogens producing traveler’s diarrhoea. Antimicrob Agents Chemother. 2001;45:643–4.10.1128/AAC.45.2.643-644.2001
   PubMed Web of Science ®Google Scholar
• Frieri G, Pimpo MT, Scarpignato C. Management of colonic diverticular disease. Digestion. 2006;73:58–66.10.1159/000089780
   PubMed Web of Science ®Google Scholar
• Lanas A, Scarpignato C. Microbial flora in NSAID-induced intestinal damage: a role for antibiotics? Digestion. 2006;73:136–50.10.1159/000089789
   PubMed Web of Science ®Google Scholar
• Johnson S, Schriever C, Galang M, Kelly CP, Gerding DN. Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin Infect Dis. 2007;44:846–8.10.1086/511870
   PubMed Web of Science ®Google Scholar
• Shen B, Remzi FH, Lopez AR, Queener E. Rifaximin for maintenance therapy in antibiotic-dependent pouchitis. BMC Gastroenterol. 2008;8:26.10.1186/1471-230X-8-26
   PubMed Web of Science ®Google Scholar
• Pimentel M. Review of rifaximin as treatment for SIBO and IBS. Expert Opin Investig Drugs. 2009;18:349–58.10.1517/13543780902780175
   PubMed Web of Science ®Google Scholar
• Bass NM, Mullen KD, Sanyal A, Poordad F, Neff G, Levy CB, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010;362:1071–81.10.1056/NEJMoa0907893
   PubMed Web of Science ®Google Scholar
• Guslandi M. Rifaximin in the treatment of inflammatory bowel disease. World J Gastroenterol. 2011;17:4643–6.10.3748/wjg.v17.i42.4643
   PubMed Web of Science ®Google Scholar
• DuPont HL, Jiang ZD, Okhuysen PC, Ericsson CD, de la Cabada FJ, Ke S, et al. A randomized, double – blind, placebo-controlled trial of rifaximin to prevent travelers’ agents. Ann Intern Med. 2005;142:805–12.10.7326/0003-4819-142-10-200505170-00005
   PubMed Web of Science ®Google Scholar
• Taylor DN, Bourgeois AL, Ericsson CD, Steffen R, Jiang ZD, Halpern J, et al. Randomized, double-blind, multicenter study of rifaximin compared with placebo and with ciprofloxacin in the treatment of travelers’ diarrea. Am J Trop Med Hyg. 2006;74:1060–6.
   PubMed Web of Science ®Google Scholar
• DuPont HL, Jiang DZ, Ericsson CD, Adachi JA, Mathewson JJ, DuPont MW, et al. Rifaximin versus ciprofloxacin for the treatment of traveler’s diarrhea: a randomized, double-blind clinical trial. Clin Infect Dis. 2001;33:1807–15.10.1086/cid.2001.33.issue-11
   PubMed Web of Science ®Google Scholar
• Kim MS, Morales W, Hani AA, Kim S, Kim G, Weitsman S, et al. The effect of rifaximin on gut flora and Staphylococcus resistance. Dig Dis Sci. 2013;58:1676–82.10.1007/s10620-013-2675-0
   PubMed Web of Science ®Google Scholar
• Mullen KD, Poordad F, Rossaro L, Jamal M, Talwalkar J, Huang S, et al. Long-term efficacy and survival in patients treated with the gut-selective antibiotic rifaximin (550 mg BID) for the maintenance of remission from overt hepatic encephalopathy. J Hepatol. 2011;54:S49.10.1016/S0168-8278(11)60111-6
   Google Scholar
• Debbia EA, Maioli E, Roveta S, Marchese A. Effect of rifaximin on bacterial virulence mechanisms at supra and sub-inhibitory concentration. J Chemother. 2008;20:61–9.
   Web of Science ®Google Scholar
• Calanni F, Renzulli C, Barbanti M, Viscomi GC. Rifaximin: beyond the traditional antibiotic activity. J Antibiot (Tokyo). 2014;67:667–70.10.1038/ja.2014.106
   PubMed Web of Science ®Google Scholar
• Dwyer DJ, Collins JJ, Walker GC. Unraveling the physiological complexities of antibiotic lethality. Annu Rev Pharmacol Toxicol. 2015;55:313–32.10.1146/annurev-pharmtox-010814-124712
   PubMed Web of Science ®Google Scholar
• McLean RJC, Pierson LS, Fuqua C. A simple screening protocol for the identification of quorum signal antagonists. J Microbiol Methods. 2004;58:351–60.10.1016/j.mimet.2004.04.016
   PubMed Web of Science ®Google Scholar
• European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters Version 4.0 [software]. 2014 Jan 14.
   Google Scholar
• Molinari G, Guzman CA, Pesce A, Schito GC. Inhibition of Pseudomonas aeruginosa virulence factors by sub-inhibitory concentrations of azithromycin and other macrolide antibiotics. J Antimicrob Chemother. 1993;31:681–8.10.1093/jac/31.5.681
   PubMed Web of Science ®Google Scholar
• Rutherford JC. The emerging role of urease as a general microbial virulence factor. PLoS Pathog. 2014;10:e1004062.10.1371/journal.ppat.1004062
   Google Scholar
• Gellatly SL, Hancock RE. Pseudomonas aeruginosa: new insights into pathogenesis and host defenses. Pathog Dis. 2013;67:159–73.10.1111/2049-632X.12033
   PubMed Web of Science ®Google Scholar
• Venturi V. Regulation of quorum sensing in Pseudomonas. FEMS Microbiol Rev. 2006;30:274–91.10.1111/j.1574-6976.2005.00012.x
   PubMed Web of Science ®Google Scholar
• Fulghesu L, Giallorenzo C, Savoia D. Evaluation of different compounds as quorum sensing inhibitors in Pseudomonas aeruginosa. J Chemother. 2007;19:388–90.10.1179/joc.2007.19.4.388
   PubMed Web of Science ®Google Scholar
• Castillo-Juárez I, Toshinari M, Ayerim Mandujano-Tinoco E, Tomàs M, Perez-Eretza B, Garcia-Contreras SJ, et al. Role of quorum sensing in bacterial infections. World J Clin Cases. 2015;3:575–98.
   PubMed Web of Science ®Google Scholar
• Gonzales PR, Pesesky MW, Bouley R, Ballard A, Biddy BA, Suckow MA, et al. Synergistic, collaterally sensitive β-lactam combinations suppress resistance in MRSA. Nat Chem Biol. 2015;11:855–61.10.1038/nchembio.1911
   PubMed Web of Science ®Google Scholar
• Rivkin A, Gim S. Rifaximin: new therapeutic indication and future directions. Clin Ther. 2011;33:812–27.10.1016/j.clinthera.2011.06.007
   PubMed Web of Science ®Google Scholar